Oncology Trials
- Home>Academics>Colleges Schools>Clinicalresearch>Trial Category>Oncology Trials
Oncology Clinical Trials
Clinical trials in Oncology provide an important step in discovering new treatments. You can browse the list of current clinical trials below to learn more.
Trials
A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator’s Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)
Sponsor: Regeneron Pharmaceuticals
NCT06091254
First-in-human Study of DB-1305 for Advanced/Metastatic Solid Tumors
A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects With Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc
NCT05438329
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
A Randomized, Phase 3, Open-label Study to Evaluate SGN-B6A Compared With Docetaxel in Adult Subjects With Previously Treated Non-small Cell Lung Cancer
Sponsor: Seagen Inc
NCT06012435
A study to evaluate the clinical validity of a ctDNA-based MRD test designed to detect breast cancer progression or recurrence following surgery
MONITOR-Breast: Monitoring cell-free tumor DNA as a marker of recurrence in Breast Cancer
Sponsor: Myriad Genetics
Learn MoreA Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator’s Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)
Sponsor: Regeneron Pharmaceuticals
NCT06091254
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors (Including Cervical, Urothelial, Ovarian, and Prostate Cancer)
A Multicenter, Open-label, Phase 2, Basket Study to Evaluate the Efficacy and Safety of SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors
Sponsor: Klus Pharma Inc
NCT 05642780
Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
A Phase 1b/2a Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of TU2218, an Oral TGFβR Serine/Threonine Kinase Inhibitor, Administered in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Sponsor: TiumBio Co, Ltd
NCT05784688
A Study to Evaluate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
A Randomized, Open-label Study of HLX10 Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sponsor: Shanghai Henlius Biotech
NCT05468489
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)
A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) vs Fulvestrant in Participants with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease
Sponsor: Pfizer
NCT05654623
A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
A Phase 1, Multicenter, Open-label, First-in-human Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
Sponsor: MediLink Therapeutics
NCT05653752
Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy
Sponsor: iTeos Belgium SA
NCT05403385
A Study to Evaluate the Efficacy and Safety of HLX10 in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 or Placebo in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
Sponsor: Shanghai Henlius Biotech
NCT05353257
Metastatic Pancreatic Ductal Adenocarcinoma Study
A Randomized, Double-Blind, Placebo-Controlled Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma
Sponsor: Panbela Therapeutics
NCT05254171
Relapsed/Refractory Follicular Lymphoma Study
Symphony-1: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphoma
Sponsor: Epizyme, Inc
NCT04224493
Relapsed/Refractory Diffuse Large B-Cell Lymphoma Study
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Sponsor: Karyopharm Therapeutics Inc
NCT04442022
Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer Study
A Phase 1b, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-ADC, in Combination with Pembrolizumab, an Anti-PD-1 Antibody, in Subjects with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Daiichi Sankyo, Inc
NCT04042701